The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2019 | MM: BTD plus a monoclonal antibody
Amrita Krishnan
• 13 Sep 2019
Amrita Krishnan, MD, City of Hope, Duarte, CA, outlines what was discussed at the ‘treatment of newly diagnosed myeloma transplant eligible’ plenary session she chaired at the International Myeloma Workshop (IMW) 2019, held in Boston, MA. The CASSIOPEIA study (NCT02541383) was the key point of discussion.
